The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
30,000 sq. ft. multispeciality facility aims to deliver integrated care for women across every life stage
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
Healthcare operations veteran with over 23 years of experience to lead key initiatives across South India
The medtech firm strengthens its full-stack remote cardiac monitoring platform, achieves 11x revenue growth, and advances its global expansion plans
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
Pharma giant targets new standards of care
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
